Background and objective: Tuberculosis (TB) risk might be increased in patients with diabetes by factors other than hyperglycaemia, such as dyslipidaemia. Host lipids are essential energy sources used by mycobacteria to persist in a latent TB state. A potential therapy targeting cholesterol catabolism of mycobacteria has been proposed, but the potential of cholesterol-lowering drugs as anti-TB therapy is unclear. The purpose of this study was to determine the effects of ezetimibe, a 2-azetidinone cholesterol absorption inhibitor, on intracellular mycobacteria survival and dormancy. Methods: Intracellular mycobacteria survival was determined by measurements of ATP activity and colonyformation units (CFUs). Gene expression profiles of hypoxia-induced dormant Mycobacterium tuberculosis (Mtb) were analysed by real-time PCR. Flow cytometry and microscopy analysis were used to measure the lipid loads of human macrophages with or without ezetimibe treatment. QuantiFERON-TB Gold In-Tube (QFT-G-IT) assays were performed to diagnose latent TB infection. The levels of intracellular cholesterol/ triglyceride were measured by an enzymatic fluorometric method. Results: Ezetimibe was capable of effectively lowering intracellular growth of Mtb and hypoxia-induced dormant Mtb. There was a significant decrease in Mtb growth in leucocytes from ezetimibe-treated patients with diabetes in terms of ATP levels of intracellular mycobacteria and CFU formation. Also, patients receiving ezetimibe therapy had a lower prevalence of latent TB and had lower intracellular lipid contents. Conclusion: Ezetimibe, which is a currently marketed drug, could hold promise as an adjunctive, hostdirected therapy for TB.
INTRODUCTION
Multiple studies have reported that subjects with diabetes mellitus (DM) are at a threefold higher risk for progression from latent tuberculosis (TB) infection (LTBI) to active disease. 1, 2 Hypercholesterolaemia, a common co-morbidity of diabetes, might synergize with DM to further exacerbate TB pathology in human hosts. 3 Impaired adaptive immunity against TB was found in apolipoprotein E-deficient mice fed with a high-cholesterol diet and elevated serum cholesterol contributed to this effect. 4 However, the impact of hypercholesterolaemia on TB immunity is more complex than appreciated by total serum cholesterol alone.
SUMMARY AT A GLANCE
This study provides evidence that the cholesterollowering drug ezetimibe is capable of reducing intracellular mycobacteria growth, and diabetes mellitus (DM) patients receiving ezetimibe therapy have lower prevalence of latent tuberculosis (TB). Our data suggest that ezetimibe treatment not only combats hypercholesterolaemia, but also may have therapeutic potential against TB.
due to the imbalance between the influx and efflux processes of cholesterol transport in diabetes, [6] [7] [8] could cause cytotoxicity 9 and should be considered as a factor that affects host immunity against TB. 10 While the effect of hypercholesterolaemia on TB infection is complex 11 and needs further clarification, a potential therapy targeting mycobacteria cholesterol catabolism has been proposed. 12, 13 The effects of cholesterol-lowering drugs on TB have also been investigated, specifically those of tetrahydrolipstatin 14, 15 and statin therapies. [16] [17] [18] [19] [20] While many anti-TB treatments have been proposed, there have been very few, if any, drugs proposed that are both cholesterol-lowering and antimicrobial. Ezetimibe is a 2-azetidinone cholesterol absorption inhibitor that targets the Niemann-Pick C1-like 1 cholesterol transporter. 21 A number of clinical trials have shown the effectiveness of ezetimibe in lowering cholesterol and triglyceride levels. [22] [23] [24] In addition, ezetimibe contains a β-lactam ring that makes it a likely antibiotic. In this study, we hypothesized that ezetimibe would inhibit intracellular mycobacteria survival in human macrophages through its antimicrobial and intracellular cholesterol-lowering effects. The purpose of the study was to investigate the effectiveness of the unexplored ezetimibe-based therapy on TB-infected macrophages using a human macrophage, dormant TB model.
METHODS

Patients
DM patients receiving and not receiving ezetimibe (10mg/day) therapy for a minimum of 3 months were recruited at MacKay Memorial Hospital (Taipei, Taiwan). The clinical characteristics of these patients are described in Tables S1 and S2 (Supplementary Information) . The clinical and laboratory data were collected and acquired from medical records. Each blood sample was processed within 6 h of collection and isolated leucocytes were stored at −80 C until further examination. This study was approved by the Institutional Review Board of MacKay Memorial Hospital (Taipei, Taiwan), and written informed consent was obtained from each participant.
Cells culture and Mtb infection
Non-disease human blood samples were obtained from the Taiwan Blood Service Foundation (Taipei, Taiwan) following written informed consent. Peripheral blood mononuclear cells were isolated from whole blood by means of Ficoll-Paque (Amersham Biosciences, Uppsala, Sweden) gradient centrifugation. Cells were first incubated with CD14 microbeads (Miltenyi Biotec GmbH, Bergish Gladbach, Germany) and then magnetized to separate out the CD14-positive cells. Macrophages were differentiated from monocytes after 6 days of culture in RPMI 1640 medium (GIBCO/Life Technologies, Grand Island, NY, USA) with 10% foetal bovine serum (FBS; Biological Industries, Haemek, Israel) in the presence of 50 U/mL recombinant human GM-CSF (Peprotech Ltd, RockyHill, NJ, USA) as previously described. 25 These cells were seeded in 12-well plates at a density of 8 × 10 5 cells per mL in a volume of 1-mL RPMI-1640 medium supplemented with 10% FBS. In the experiment of ezetimibe treatment combined with anti-TB drugs, THP-1-derived macrophages that differentiated from phorbol 12-myristate 13- 
In vitro killing kinetics against Mtb
Mtb was cultured in 7H9 medium adjusted to a McFarland 0.5 standard (CMP, Taipei, Taiwan). The standardized batch was then used as inocula after 10-fold dilution in 7H9 medium. To estimate the bactericidal effect of ezetimibe, Mtb was cultured in 7H9 medium with varying concentrations of ezetimibe and mycobacterial growth was measured by absorbance at 600 nm (optical density, OD) with a spectrophotometer (Metertech, Taipei, Taiwan).
Miscellaneous methods
Procedures for ezetimibe preparation, flow cytometry, oil red O staining, colony-forming units (CFUs), ATP measurement and quantitative measurement of intracellular cholesterol/triglyceride content are provided in Appendix S1 (Supplementary Information).
RNA isolation and quantitative real-time RT-PCR
Intracellular mycobacteria RNA were isolated and real-time reverse transcription PCR (RT-PCR) was performed as previously described. 26 Additional details are provided in Appendix S1 and Table S3 (Supplementary Information). The calculated threshold cycle (Ct) value for each gene of interest was normalized to the Ct value for 16S and the fold expression was calculated.
Statistical analysis
Results were compared by Fisher's exact test for categorical variables and paired t-test or unpaired t-test for continuous variables as appropriate. Data are reported as the mean AE SEM. Statistical analysis was performed using Prism 6.0 software (GraphPad Software, La Jolla, CA, USA). Two-sided tests were used and a P-value of <0.05 was considered statistically significant.
RESULTS
Ezetimibe reduced both extracellular growth and intracellular survival of Mtb
To investigate how ezetimibe (Ezetrol, MSD ScheringPlough, Las Piedras, Puerto Rico, USA) impacts the growth of Mtb, mycobacterial growth exposure to increasing concentrations of ezetimibe was estimated by either OD (Fig. 1A ) or colony formation (Fig. S1 , Supplementary Information). The growth of mycobacteria was found to be reduced following treatment with ezetimibe. Ezetimibe was also shown to reduce cholesterol uptake by human macrophages in a dosedependent manner (Fig. 1B) , confirming that ezetimibe was indeed an inhibitor of cholesterol uptake. Furthermore, using these data, we chose 20 μg/mL ezetimibe as the working concentration in the following experiments.
Macrophages were infected with Mtb and foamy cells were observed at days 3 and 7 by oil red O staining. By day 7, the number of positively stained macrophages had increased following Mtb infection (12.6 AE 3.1%) compared with that in the non-infected culture (8.2 AE 2.1%). After exposure to ezetimibe for 24 h and in culture for another 7 days, macrophages formed less foamy cells (5.9 AE 1.9%; Fig. 1C ). The ratio of foamy cells formed in the ezetimibe-treated group versus the non-ezetimibetreated group was significantly reduced (control: ezetimibe = 100%: 49.3 AE 12.5%, P = 0.027). To assess the effect of ezetimibe on Mtb uptake by macrophages, FITClabelled Mtb and CFU assay were performed. Our results showed that Mtb uptake by macrophages was not affected by ezetimibe (Appendix S1 and Fig. S2 , Supplementary Information). In addition, CFU assays were performed to determine whether treatment with ezetimibe affected intracellular Mtb growth. After infecting macrophages and incubating with or without cholesterol supplement for 1 and 2 days, the macrophage lysates (containing Mtb) were cultured for 3 weeks. When cholesterol was not supplemented, the CFU counts of Mtb with ezetimibe treatment (CFU counts 115 580 AE 24 143) were found to be significantly less than that of control (CFU counts 193 900 AE 45 836, P = 0.009) in 1-day incubation as well as in 2-day incubation (CFU counts of ezetimibe Fig. 1D ). These data show that ezetimibe is capable of lowering intracellular growth of Mtb and the effect can be reversed by excess cholesterol supplementation.
We next evaluated the efficacy of ezetimibe adjunctive therapy when used in combination with the firstline anti-TB drugs including isoniazid (INH), rifampicin (RIF), ethambutol (EMB) or pyrazinamide (PZA). As shown in Figure 2 , ezetimibe reduced the intracellular Mtb growth in THP-1-derived macrophages and enhanced the efficacy of the conventional anti-TB drugs INH and RIF (CFU counts of INH 50 000 AE 13 166 vs INH plus ezetimibe 20 000 AE 9661, P = 0.005; CFU counts of RIF 43 333 AE 14 757 vs RIF plus ezetimibe 10 000 AE 3651, P = 0.048). The results suggest a potential for ezetimibe as an adjunctive drug for conventional treatment.
Ezetimibe retarded metabolic activity of hypoxia-induced dormant mycobacteria
To investigate the effect of ezetimibe treatment on dormant TB, we applied hypoxic stress to generate a dormant Mtb population. Next, we examined the status of intracellular mycobacteria by monitoring the expression of dormancy-associated genes and colony-forming abilities. Compared with the results of the normoxic group, there was an increased expression of the following dormancy-associated genes of intracellular mycobacteria in the hypoxic group: isocitrate lyase (icl), heat shock protein (hspX), triacylglycerol synthase (tgs1) and dormancy survival regulator (dosR) (Fig. 3A) . After 3 days of culture, the bacteria that exhibited these dormant characteristics also stopped replicating. Bacterial growth in hypoxia was also significantly lower than bacterial growth in normoxia at day 3 (P = 0.026; Fig. S3, Supplementary Information) . We treated the hypoxia-induced dormant mycobacteria with ezetimibe on the third day for 24 h and performed the same analyses. hspX, tgs1 and dosR genes (Fig. 3B) as well as CFU counts (Fig. 3C ) were found to be inhibited following exposure to increasing concentrations of ezetimibe. Because ATP synthesis is essential for the viability of hypoxic non-replicating mycobacteria, 27, 28 intracellular ATP levels were measured in dormant Mtb. When exposed to ezetimibe, dormant mycobacteria demonstrated reduced ATP levels (Fig. 3D) . In summary, ezetimibe could not only reduce the growth of mycobacteria, but also significantly suppressed the metabolic activities of dormant mycobacteria required for their long-term persistence.
Increased resistance to Mtb infection of leucocytes from ezetimibe-treated DM patients
Type II DM patients with hyperlipidaemia could have higher risks of TB infection and reactivation, so we explored the lipid-reducing and possible anti-TB benefits of using ezetimibe to treat these patients. As ezetimibe was found to inhibit Mtb growth, we proposed that Mtb would be less effective at infecting the leucocytes of DM patients receiving ezetimibe therapy. We collected the blood samples from DM patients with or without a history of 3-month ezetimibe therapy. The clinical characteristics of studied subjects are summarized in Table S1 (Supplementary Information). The leucocytes of DM patients were infected with Mtb (MOI = 1) and incubated for 3 days. Growth of Mtb in leucocytes from ezetimibe-treated patients significantly decreased in terms of both CFU and ATP levels from intracellular mycobacteria (Fig. 4) . 
Ezetimibe treatment is associated with reduced prevalence of latent TB
To investigate the protective effects of ezetimibe on LTBI, DM patients receiving different cholesterol-lowering drugs were recruited and QFT-G-IT assays (Cellestis, Chadstone, Victoria, Australia) were performed to diagnose LTBI. The clinical characteristics of studied subjects are summarized in Table S2 (Supplementary Information). The therapeutic regimen of patients was provided, and it was found that there were no significant differences between patients that did or did not take metformin, an oral hypoglycaemic with possible anti-TB effects. 29 We confirmed that ezetimibe therapy was associated with a reduced QFT-G-IT-positive rate (27.3%) when compared with patients treated with alternative cholesterol-lowering drugs (non-ezetimibe, 54.5%, Fisher's exact test, P = 0.041; Fig. 5A ), thus implying that ezetimibe reduces the likelihood of acquiring LTBI. While comparing the cholesterol level in peripheral serum, there was no statistical difference in patients receiving ezetimibe and alternative cholesterol-lowering drugs (Table  S2 , Supplementary Information). Furthermore, intracellular cholesterol levels of ezetimibe-treated DM patients were significantly lower than those in non-ezetimibe-treated DM patients (Fig. 5B) . The same trend was also observed for intracellular levels of triglyceride (Fig. S4 , Supplementary Information). Together, these findings suggest that ezetimibe treatment is associated with a reduced intracellular lipid content, which may hinder intracellular TB survival. were infected with Mycobacterium tuberculosis (Mtb) at a multiplicity of infection (MOI) of 1 for 1 h, washed and incubated in the hypoxia chamber for 3 days. Gene transcript levels were expressed as fold change relative to the normoxia group following normalization with 16S-rRNA as the reference gene (n = 3 per group). (B) On the third day of hypoxia condition, ezetimibe was added for 24 h and intracellular mycobacteria were collected. The dormancy-associated genes of intracellular mycobacteria were found to be inhibited as exposing to ezetimibe. Data represented the fold changes relative to untreated controls (n = 6 per group; icl, isocitrate lyase; dosR, dormancy survival regulator;
tgs1, triacylglycerol synthase;
hspX, heat shock protein). (C) In the same experimental procedure, incubation of the intracellular dormant mycobacteria treated with ezetimibe was reduced as determined by enumeration of colony-formation unit (CFU; n = 6 per group). (D) Ezetimibe reduced intracellular Mtb ATP activity (n = 5 per group). Data were mean AE standard error of the mean and statistical difference was analysed with the paired t-test. 
DISCUSSION
In this study, ezetimibe was found to inhibit the growth of intracellular mycobacteria and was capable of inhibiting the formation of foamy macrophages, leading to the deprivation of the major nutrients necessary for intracellular Mtb survival. Also, ezetimibe therapy was found to suppress the expression of the dormancyrelated genes required for mycobacterium persistence in its latent state and also lowered the CFUs and the ATP levels of hypoxic-induced dormant mycobacteria. The reduced activity of dormant Mtb after exposure to ezetimibe implies that ezetimibe may have therapeutic potential to prevent the relapse of LTBI.
There have been other studies that show the importance of host lipids-cholesterol 30, 31 and triglyceride 32, 33 -as a major source of nutrition for Mtb. 34, 35 By further exploring various lipid-targeting treatments, latent TB could be potentially controlled. A possible approach is to target the cholesterol catabolic enzymes of bacteria, 12, 13 but another may be to lower cholesterol levels in humans. Statins, a cholesterol-lowering class of drugs targeting 3-hydroxy-3-methylglutarylcoenzymeA reductase, may protect hosts by counteracting Mtb-induced phagosomal maturation arrest 19 and may also have potential additive effects to first-line TB treatment. 20 A retrospective study found that statin therapy may decrease the incidence of active TB infection in DM patients older than 65 years. 17 In contrast, another study demonstrated that statin use among DM patients did not yield any protective effects on TB incidence. 16 Our study, however, found no benefit in treating Mtb-infected macrophages with statins (Fig. S5 ). In addition, DM patients receiving statin therapy had higher QFT-G-IT-positive ratios and intracellular lipid content than DM patients receiving ezetimibe therapy. Although statin and ezetimibe are both classified as cholesterol-lowering agents capable of reducing serum cholesterol levels, they operate through different pharmacological mechanisms that may lead to varying intracellular lipid levels. 36, 37 Using ezetimibe therapy to limit the nutrients needed by intracellular mycobacteria to thrive may control bacterial growth. There may be other mechanisms by which ezetimibe enhance the killing of intracellular Mtb. It has been shown that the accumulation of cholesterol in macrophages would impair the maturation of phagosomes, 38 which could be overcome by ezetimibe through reduction of cholesterol uptake. 39 In addition, ezetimibe is also found to have a positive effect on autophagy, which may also enhance the killing of intracellular Mtb. 40 DM patients with latent TB have an increased risk of developing active TB via reactivation.
1,2 As a result, we have shown that ezetimibe therapy in DM patients (10 mg/day) can increase protection against in vitro Mtb infection. Due to the significant statistical difference between the latent statuses and intracellular lipid contents in patients taking ezetimibe and nonezetimibe cholesterol-lowering drugs, there seems to be a trend in favour of ezetimibe. Therefore, to assess the value of ezetimibe in preventing the reactivation of TB, future studies should be designed to prospectively investigate the incidence of relapsing TB in DM patients with positive QFT-G-IT, including study drugs in different doses.
Our study provides considerable evidence supporting that ezetimibe could potentially be utilized as a therapeutic agent against Mtb. The enhanced effect of ezetimibe with some of the anti-TB drugs implies ezetimibe's potential as an adjunctive, host-directed therapy for latent TB. Because this study was focused solely on in vitro data, further studies will need to be addressed by in vivo animal studies before appropriate conclusions can be made about using ezetimibe in anti-TB therapy. Nevertheless, ezetimibe is already an approved drug in the market, making it convenient to focus future research on this prospective treatment for LTBI. 
